Gene Biotherapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Jemapete Christopher J, was filed 18 Mar 2021.
Gene Biotherapeutics, Inc.: what insiders have been doing
Gene Biotherapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). No insider at Gene Biotherapeutics, Inc. has published a filing in the past twelve months. The most recent one dates from 18 March 2021.
Since 2007, the database holds 2 purchases and no sales by insiders of the company.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2013FY ended December 2013 · cache
- 300,000 shares@ US$0.039912.9% of flowCommon StockSEC:0001493152-21-006314:0Canonical exit: 14 Jun 2021 (T+90)
- 200,000 shares@ US$0.40287.1% of flowCommon StockSEC:0001493152-21-006314:1Canonical exit: 15 Jun 2021 (T+90)
- 15,263 sharesCommon StockSEC:0001181431-07-065792:0
- 88,858 sharesCommon StockSEC:0001181431-07-025217:0
4 of 4 declarations
About Gene Biotherapeutics, Inc.
Gene Biotherapeutics, Inc. is a company focused on developing gene therapies to treat various diseases. It is listed on the XNAS market.
